Dexcom anticipates $5.20B-$5.25B 2026 revenue while authorizing another $1B buyback
Read original article on Breaking News on Seeking Alpha →Related news
- Merit Medical targets $4.33-$4.37 non-GAAP EPS in 2026 while adding Solo Pace for ~$45M Business Corporate United States
- PennyMac outlines $160M annualized expense cuts as it expects Q4 2026 adjusted ROE to remain near current levels Business Corporate United States
- SCI expects $1.10-$1.20 Q4 2026 EPS as it targets preneed momentum despite weaker funeral volumes Business Corporate United States
- Shell targets $23B-$25B 2026 cash CapEx while launching a $5B buyback and integrating ARC Resources Business Corporate United Kingdom
- Reddit forecasts Q4 2026 revenue of $1B-$1.03B amid logged-in-only testing plans Technology Social Media United States
-
Positive Breakout: 7 stocks cross above their 200 DMAs
Economy
Markets
India
- Ryan Specialty signals 2026 adjusted EBITDAC margin down around 50 bps while launching Tera Underwriters with $625M capacity Business Corporate
- CarParts.com outlines Q4 markers for A-Premium above $55M run rate and last-mile ramp to 300,000 packages annually Business Corporate